- Home
- AMRN vs NRO Comparison
AMRN vs NRO Comparison
Compare AMRN & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- NRO
- Stock Information
- Founded
- AMRN 1989
- NRO 2003
- Country
- AMRN Ireland
- NRO United States
- Employees
- AMRN N/A
- NRO N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- NRO Finance/Investors Services
- Sector
- AMRN Health Care
- NRO Finance
- Exchange
- AMRN Nasdaq
- NRO Nasdaq
- Market Cap
- AMRN 189.2M
- NRO 170.5M
- IPO Year
- AMRN 1993
- NRO N/A
- Fundamental
- Price
- AMRN $0.55
- NRO $3.31
- Analyst Decision
- AMRN Buy
- NRO
- Analyst Count
- AMRN 1
- NRO 0
- Target Price
- AMRN N/A
- NRO N/A
- AVG Volume (30 Days)
- AMRN 1.1M
- NRO 239.4K
- Earning Date
- AMRN 02-27-2025
- NRO 01-01-0001
- Dividend Yield
- AMRN N/A
- NRO 11.41%
- EPS Growth
- AMRN N/A
- NRO N/A
- EPS
- AMRN N/A
- NRO N/A
- Revenue
- AMRN $241,021,000.00
- NRO N/A
- Revenue This Year
- AMRN N/A
- NRO N/A
- Revenue Next Year
- AMRN N/A
- NRO N/A
- P/E Ratio
- AMRN N/A
- NRO N/A
- Revenue Growth
- AMRN N/A
- NRO N/A
- 52 Week Low
- AMRN $0.43
- NRO $2.51
- 52 Week High
- AMRN $1.36
- NRO $3.45
- Technical
- Relative Strength Index (RSI)
- AMRN 50.48
- NRO 38.13
- Support Level
- AMRN $0.55
- NRO $3.33
- Resistance Level
- AMRN $0.61
- NRO $3.45
- Average True Range (ATR)
- AMRN 0.04
- NRO 0.07
- MACD
- AMRN -0.00
- NRO -0.01
- Stochastic Oscillator
- AMRN 26.56
- NRO 5.56
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").